DGAP-News: Andera Partners / Key word(s): Personnel Andera Partners strengthens its Life Sciences team with a new partner 07.07.2022 / 10:15 The issuer is solely responsible for
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C.
/PRNewswire/ Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for.
DGAP-News: Andera Partners / Key word(s): Financing Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension 08.06.2022 / 14:05 The issuer is solely responsible for the content of th.
DGAP-News: Andera Partners / Key word(s): Financing Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs 03.05.2022 / 11:05